X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
chills - chemically induced (52) 52
male (52) 52
female (49) 49
fever - chemically induced (47) 47
middle aged (44) 44
adult (38) 38
aged (32) 32
index medicus (31) 31
chills (21) 21
fever (17) 17
treatment outcome (17) 17
nausea - chemically induced (14) 14
oncology (13) 13
adolescent (12) 12
amphotericin b - adverse effects (12) 12
dosage (12) 12
dose-response relationship, drug (11) 11
drug administration schedule (11) 11
infusions, intravenous (11) 11
aged, 80 and over (10) 10
infectious diseases (10) 10
therapy (10) 10
vomiting - chemically induced (10) 10
immunology (9) 9
antibodies, monoclonal - adverse effects (8) 8
antineoplastic agents - adverse effects (8) 8
chemotherapy (8) 8
fatigue - chemically induced (8) 8
headache - chemically induced (8) 8
time factors (8) 8
young adult (8) 8
amphotericin b - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
child (7) 7
microbiology (7) 7
rituximab (7) 7
safety (7) 7
amphotericin b - therapeutic use (6) 6
animals (6) 6
antibodies, monoclonal - administration & dosage (6) 6
antifungal agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cancer (6) 6
hematology (6) 6
immunotherapy (6) 6
risk factors (6) 6
acetaminophen - therapeutic use (5) 5
analysis (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
child, preschool (5) 5
clinical trials (5) 5
dermatology (5) 5
diarrhea - chemically induced (5) 5
double-blind method (5) 5
dyspnea - chemically induced (5) 5
follow-up studies (5) 5
hypotension - chemically induced (5) 5
infections (5) 5
interferon-alpha - administration & dosage (5) 5
interferon-alpha - adverse effects (5) 5
melanoma - drug therapy (5) 5
patients (5) 5
pharmacokinetics (5) 5
recombinant proteins - adverse effects (5) 5
remission induction (5) 5
retrospective studies (5) 5
side effects (5) 5
studies (5) 5
anti-bacterial agents - adverse effects (4) 4
antimetabolites, antineoplastic - administration & dosage (4) 4
antimetabolites, antineoplastic - adverse effects (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - therapeutic use (4) 4
blood (4) 4
chills - drug therapy (4) 4
cold temperature (4) 4
combined modality therapy (4) 4
drug dosages (4) 4
drug therapy (4) 4
efficacy (4) 4
fluorouracil - administration & dosage (4) 4
health aspects (4) 4
incidence (4) 4
interleukin-2 - adverse effects (4) 4
lipids (4) 4
management (4) 4
pain - chemically induced (4) 4
pharmacology & pharmacy (4) 4
public health (4) 4
public, environmental & occupational health (4) 4
recombinant proteins - administration & dosage (4) 4
temperature (4) 4
toxicity (4) 4
tumors (4) 4
abdominal pain - chemically induced (3) 3
alpha (3) 3
analgesics, non-narcotic - therapeutic use (3) 3
anti-bacterial agents - administration & dosage (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 587 - 598
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 25, pp. 2780 - 2788
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 36 - 44
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 04/2016, Volume 65, Issue 4, pp. 383 - 392
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2002, Volume 100, Issue 9, pp. 3115 - 3120
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 06/2014, Volume 7, Issue 1, pp. 44 - 44
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2006, Volume 44, Issue 4, pp. 671 - 678
: Recombinant human albumin-interferon alfa (alb-IFN) is a novel 85.7-kD recombinant protein consisting of interferon alfa-2b genetically fused to human serum... 
Genotype 1 | Albumin-interferon alfa | Chronic hepatitis C | Viral kinetics | Pharmacokinetics | albumin-interferon alfa | PLUS RIBAVIRIN | THERAPY | VIRUS | chronic hepatitis C | pharmacokinetics | genotype 1 | viral kinetics | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Serum Albumin - administration & dosage | Half-Life | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Recombinant Proteins - pharmacokinetics | Fatigue - chemically induced | Recombinant Proteins - adverse effects | Arthralgia - chemically induced | Serum Albumin, Human | Serum Albumin - adverse effects | Dose-Response Relationship, Drug | Chills - chemically induced | Injections, Subcutaneous | Interferon-alpha - pharmacokinetics | Adult | Female | Headache - chemically induced | Serum Albumin - pharmacokinetics | Drug Tolerance | RNA, Viral - analysis | Genotype | Hepatitis C, Chronic - drug therapy | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Interferon-alpha - adverse effects | Hepatitis C, Chronic - genetics | Antiviral agents | Safety and security measures | RNA | Fatigue testing machines | Materials | Clinical trials | Antiship missiles | Fatigue | Serum albumin | Biological response modifiers | Recombinant proteins | Genetic aspects | Universities and colleges | Hepatitis C | Health aspects
Journal Article